Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease
Author:
Publisher
Springer Science and Business Media LLC
Subject
Gastroenterology,Physiology
Link
https://link.springer.com/content/pdf/10.1007/s10620-023-07822-7.pdf
Reference38 articles.
1. Baumgart DC, Sandborn WJ. “Crohn’s disease,” (in eng). Lancet 2012;380:1590–1605. https://doi.org/10.1016/s0140-6736(12)60026-9.
2. Deepak P, Sandborn WJ. “Ustekinumab and Anti-Interleukin-23 Agents in Crohn’s Disease,” (in eng). Gastroenterol Clin North Am 2017;46:603–626. https://doi.org/10.1016/j.gtc.2017.05.013.
3. Peluso I, Pallone F, Monteleone G. “Interleukin-12 and Th1 immune response in Crohn’s disease: pathogenetic relevance and therapeutic implication,” (in eng). World J Gastroenterol 2006;12:5606–5610. https://doi.org/10.3748/wjg.v12.i35.5606.
4. Neurath MF. “IL-23: a master regulator in Crohn disease,” (in eng). Nat Med 2007;13:26–28. https://doi.org/10.1038/nm0107-26.
5. Feagan BG, Sandborn WJ, Gasink C et al. “Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease,” (in eng). N Engl J Med 2016;375:1946–1960. https://doi.org/10.1056/NEJMoa1602773.
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Physiologically-based pharmacokinetic modeling to predict the exposure and provide dosage regimens of Ustekinumab in pediatric patients with inflammatory bowel disease;European Journal of Pharmaceutical Sciences;2024-08
2. Long-Term Outcomes of Intravenous Ustekinumab Maintenance Treatment in Patients With Loss of Response to Subcutaneous Dosing;Inflammatory Bowel Diseases;2024-07-31
3. Relationship between Ustekinumab trough concentrations and clinical, biochemical and endoscopic outcomes in Crohn’s disease: A multi-center nationwide retrospective study (TARGET STUDY);Medicine;2024-07-05
4. Single or continuous multiple intravenous re-induction in Crohn's disease patients who lost response to ustekinumab: Evidence from real-world data;Digestive and Liver Disease;2024-05
5. Medical management of pediatric inflammatory bowel disease;Seminars in Pediatric Surgery;2024-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3